The maximum retail price of 390 non-scheduled cancer medicines have been reduced by up to 87 per cent, which would result in annual savings of around Rs 800 crore for the patients, the government said Friday.
The National Pharmaceutical Pricing Authority (NPPA) on February 27 had brought 42 non-scheduled anti-cancer drugs under price control, capping trade margin at 30 per cent.
Manufacturers and hospitals were directed to convey the revised MRP, to be effective from March 8, based on the trade margin formula.
